Cognition Therapeutics

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Cognition Therapeutics sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials none currently recruiting 7 completed early-phase tilt top decile by trial count

Cognition Therapeutics: 9 sponsored US clinical trials, none currently recruiting.

Cognition Therapeutics sponsors 9 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 7 completed. 0 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Mild to Moderate Alzheimer's Disease, with 1 trials.

Top-decile sponsor footprint

Cognition Therapeutics ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Indexed trials (enrollment closed)

9 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 2

A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

NCT05531656
TERMINATED Phase 2

Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).

NCT05893537
COMPLETED Phase 2

Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies

NCT05225415
COMPLETED Phase 1

Study to Assess the Pharmacokinetics of CT1812 in Older Healthy Volunteers

NCT05248672
COMPLETED Phase 1

Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects

NCT05225389
COMPLETED Phase 2

A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

NCT03507790
COMPLETED Phase 1

Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease

NCT03522129
COMPLETED Phase 1

Effect of CT1812 Treatment on Brain Synaptic Density

NCT03493282
COMPLETED Phase 1

Drug Interaction Study of CT1812 in Healthy Volunteers

NCT03716427

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 4

Therapeutic Areas

Mild to Moderate Alzheimer's Disease 1
Early Alzheimer's Disease 1
Alzheimer Disease 1

How the Cognition Therapeutics early-phase archive is shaped

9 indexed studies, none listed as recruiting (0% open); 7 completed (78%).

Phase mix: 0 late (III/IV) vs 9 early (I/II) (early-phase heavy).

Top condition: Mild to Moderate Alzheimer's Disease (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Cognition Therapeutics: archived-pipeline peers nationwide

Peers matched on 9 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Cognition Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40%50% Total trials Recruiting share Cognition Therapeutics4D Molecular Therapeutics9 Meters BiopharmaAadi BioscienceAblynx, a Sanofi company10xBio22nd Century Group23andMe3-C Institute for Social Development
Cognition Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Cognition Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Cognition Therapeutics page

9 registered trials is a research-attention snapshot, not an endorsement of Cognition Therapeutics or any single study.

  • None of Cognition Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Mild to Moderate Alzheimer's Disease is the condition Cognition Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Mild to Moderate Alzheimer's Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Cognition Therapeutics pipeline card: 9 registered trials from official public datasets.Report a data error.